Effect of Smad pathway activation on podocyte cell cycle regulation: an immunohistochemical evaluation

Figures & data

Table 1. Summary of the classification and the clinical parameters of patients with glomerulonephritis.

Disease	Number of patients	Age (Years)	Gender (M/F)	Creatinine (mg/dl)	Proteinuria (g/24 h)
FSGS	5	42 ± 16.6	4/1	1.87 ± 0.92	2.82 ± 1.54
MN	9	59.1 ± 20.1	5/4	1.05 ± 0.52	4.1 ± 1.83
MCD	3	30.7 ± 7.4	3/0	0.93 ± 0.15	5.75 ± 3.61
pauci-IM-GN	10	61.6 ± 12.3	4/6	3.26 ± 2.32	0.72 ± 0.87
Proliferative LN	20	33.8 ± 2.8	3/17	1.41 ± 0.73	3.56 ± 2.84
Non-proliferative  LN	10	32.2 ± 6.2	1/9	0.8 ± 1.41	2.06 ± 2.84
IGAN	10	40.7 ± 12.8	8/2	1.08 ± 0.46	1.9 ± 1.8

FSGS: Focal segmental glomerulosclerosis, MN: Membranous nephropathy, MCD: Minimal Change Disease, pauci-IM-GN: pauci-immune glomerulonephritis, LN: Lupus nephritis, IGAN: IgA nephropathy. Values expressed in mean ± std. dev.

Figure 1. Expression pSmad2/3, p300 and p57 in normal human kidney: A few glomerular cells, including all cell types, were pSmad2/3 positive (a) (arrows). Less than 30% of glomerular cells, including all cell types, were p300 positive (b). Podocyte staining for p57 in the normal kidney was abundant with a nuclear staining pattern (c). Immunopositivity for psmad2/3 and p300 (d, e,) but not for p57 (f) in a cellular crescent (arrows) (Wegener granulomatosis). Immunopositivity for psmad2/3 and p300 (g, h) but not for p57 (i) in hyperplastic lesions and microadhesions (arrows) (proliferative lupus nephritis, WHO class IV). (Figure 1a, b, d, e, g and h are reproduced from Kassimatis et al.35). Original magnification ×400.

Figure 2. Staining scores for the glomerular expression of pSmad2/3, p300 and p57 in different types of GN. (% patients). (FSGS: Focal segmental glomerulosclerosis, MN: Membranous nephropathy, MCD: Minimal Change Disease, pauci-IM-GN: pauci-immune glomerulonephritis, LN: Lupus nephritis, IGAN: IgA nephropathy.)

Kassimatis TI, Giannopoulou I, Koumoundourou D, Theodorakopoulou E, Varakis I, Nakopoulou L. Immunohistochemical evaluation of phosphorylated SMAD2/SMAD3 and the co-activator P300 in human glomerulonephritis: Correlation with renal injury. J Cell Mol Med. 2006;10(4):908–921

 Google Scholar